[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-361096-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-361096-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","neoadjuvant-nedaplatin-and-paclitaxel-regimen-with-concurrent-radiotherapy-for-esophageal-squamous-cell-carcinoma-a-single-arm-phase-ii-clinical-trial","Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma - a single-arm phase II clinical trial","","Aims: This single-arm phase II study evaluated the efficacy and safety of neoadjuvant concurrent chemoradiotherapy (CCRT) using nedaplatin and paclitaxel in locally advanced esophageal squamous cell carcinoma (ESCC). Patients & methods: Two cycles of nedaplatin plus paclitaxel (or albumin-bound paclitaxel) were given with concurrent radiotherapy (41.4–50.4 Gy) before surgery. Immunohistochemical profiling assessed biomarkers, with pathological complete response (pCR) as the primary endpoint.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/neoadjuvant-nedaplatin-and-paclitaxel-regimen-with-concurrent-radiotherapy-for-esophageal-squamous-cell-carcinoma-a-single-arm-phase-ii-clinical-trial/361096/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/neoadjuvant-nedaplatin-and-paclitaxel-regimen-with-concurrent-radiotherapy-for-esophageal-squamous-cell-carcinoma-a-single-arm-phase-ii-clinical-trial/361096.png","ImageObject",300,407,{"name":42,"@type":43},"awa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What treatment regimen was tested in this phase II trial?","Question",{"text":63,"@type":64},"Patients received two cycles of nedaplatin plus paclitaxel (or albumin-bound paclitaxel) together with concurrent radiotherapy (41.4–50.4 Gy) before surgery.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What was the primary endpoint and what was the pCR rate?",{"text":68,"@type":64},"The primary endpoint was pathological complete response (pCR) rate. Among 49 enrolled patients, 33 underwent surgery, and the pCR rate was 30.3% in the surgical cohort.",{"name":70,"@type":61,"acceptedAnswer":71},"Which immune markers showed prognostic associations?",{"text":72,"@type":64},"Higher FOXP3 expression before and after treatment was nominally associated with favorable outcomes. Upregulated TIGIT after treatment trended toward poorer prognosis in the surgical cohort, and FOXP3/TIGIT dynamics were highlighted as potential prognostic indicators.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},361096,1790290957,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","FUTURE ONCOLOGY  \n2026, VOL. 22, NO. 18, 2189–2200  \n[https://doi.org/10.1080/14796694.2026.2701490](https://doi.org/10.1080/14796694.2026.2701490)  \nRESEARCH ARTICLE     \nNeoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: a single-arm phase II clinical trial  \nTing Liu a*, Xiao Danb*, Qing Lia, Peipei Wanga, Yueyun Chena, Jiangfang Tiana, Zhen Lina, Yang Huc, Huashan Shia and Zhenyu Ding a  \naDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China; bDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; cDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China  \nABSTRACT  \nAims: To evaluate the efficacy and safety of neoadjuvant concurrent chemoradiotherapy (CCRT) utilizing nedaplatin and paclitaxel in patients with locally advanced esophageal squamous cell carcinoma (ESCC) .  \nPatients & methods: Locally advanced ESCC patients received two cycles of nedaplatin plus paclitaxel or albumin-bound paclitaxel with concurrent radiotherapy (41.4–50.4 Gy) as neoadjuvant treatment. Immunohistochemical profiling was performed on biopsies and surgical specimens. The primary endpoint was the pathological complete response (pCR) rate.  \nResults: Among 49 enrolled patients, 33 underwent surgery, yielding a pCR rate of 30.3% . Overall survival was inferior in resected patients with positive postoperative lymph nodes (HR 3.92, 95% CI 1.30–11.80, p = 0.02, log-rank p = 0.009) . Higher FOXP3 expression before (HR 0.14, 95% CI 0.02–1.26, p = 0.08, log-rank p = 0.041) and after (HR 0.23, 95% CI 0.07–0.84, p = 0.03, log-rank p = 0.015) treatment nominally contributed to favorable outcomes. Upregulated TIGIT post-treatment trended toward a poorer prognosis in this surgical cohort (HR 7.10, 95% CI 0.79–63.65, p = 0.08, log-rank p = 0.041) . Conclusion: Neoadjuvant nedaplatin and paclitaxel-based CCRT demonstrates encouraging preliminary antitumor efficacy. Tumor microenvironment profiling highlights FOXP3 and TIGIT dynamics as potential prognostic indicators. These hypothesis-generating insights warrant further validation in large-scale, randomized controlled trials. Clinical trial registration: Chinese Clinical Trial Registry ([http://www.chictr](http://www.chictr).  \n[org.cn](org.cn)), identifier is ChiCTR1900024628. Date of registration: 19 July 2019.  \nPLAIN LANGUAGE SUMMARY  \nTesting a new combination of chemotherapy and radiotherapy before surgery for esophageal cancer.  \nWhat did this study look at?  \nThis study tested a treatment for people with a common type of esophageal cancer (called esophageal squamous cell carcinoma) that had grown into nearby tissues but had not spread widely. The treatment combined two chemotherapy drugs (nedaplatin and paclitaxel) with radiation therapy, all of which were given before surgery. The goal was to see whether this approach could shrink the cancer enough to allow complete removal during surgery.  \nWhat did the study find?  \nOut of 49 people who started the treatment, 33 were able to have surgery. Among those 33, about 30.3% had no cancer left in the removed tissue. No one died from surgery complications. The most common serious side effect was a low white blood cell count, which occurred in about 31% of people.  \nWhat do the immune marker results suggest?  \nWe also studied small proteins (immune markers) in cancer samples. People whose tumors had higher levels of a marker called FOXP3 before treatment tended to live longer. Also, people whose tumors showed a decrease in another marker called TIGIT after treatment had better survival. However, these findings need to be confirmed in larger studies.  \nWhat are the limitations?  \nThis study did not compare the new treatment against a standard treatment, and the number of people was small. So the results are promising but not final proof.  \nTrial registration: ChiCTR19000","cbCaiife8ONXgldF","https://ap.wps.com/l/cbCaiife8ONXgldF","pdf",7983714,12,"English","# Abstract\n## Aims\n## Patients & methods\n## Results\n## Conclusion\n# Plain language summary\n## What did this study look at?\n## What did the study find?\n## What do the immune marker results suggest?\n## What are the limitations?\n# Article highlights\n## Key findings","[{\"question\":\"What treatment regimen was tested in this phase II trial?\",\"answer\":\"Patients received two cycles of nedaplatin plus paclitaxel (or albumin-bound paclitaxel) together with concurrent radiotherapy (41.4–50.4 Gy) before surgery.\"},{\"question\":\"What was the primary endpoint and what was the pCR rate?\",\"answer\":\"The primary endpoint was pathological complete response (pCR) rate. Among 49 enrolled patients, 33 underwent surgery, and the pCR rate was 30.3% in the surgical cohort.\"},{\"question\":\"Which immune markers showed prognostic associations?\",\"answer\":\"Higher FOXP3 expression before and after treatment was nominally associated with favorable outcomes. Upregulated TIGIT after treatment trended toward poorer prognosis in the surgical cohort, and FOXP3/TIGIT dynamics were highlighted as potential prognostic indicators.\"}]","Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma - a single-arm phase II clinical trial | PDF",1790143108,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fd6da31d4fad036b81d44da9fb1e31a.webp",983,1280,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b953d6d4ab62ceee88c0e7dfeb2fea8.webp",982,1278,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f074392761f33b19d5baaef79cd84b2.webp",981,1277,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7001c621fd64ee44e86ee9f75804dad.webp",980,1276]